CoChat

Multifaceted role for p53 in pancreatic cancer suppression

Open access

The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.

Abstract

The vast majority of human pancreatic ductal adenocarcinomas (PDACs) harbor TP53 mutations, underscoring p53’s critical role in PDAC suppression. PDAC can arise when pancreatic acinar cells undergo acinar-to-ductal metaplasia (ADM), giving rise to premalignant pancreatic intraepithelial neoplasias (PanINs), which finally progress to PDAC. The occurrence of TP53 mutations in late-stage PanINs has led to the idea that p53 acts to suppress malignant transformation of PanINs to PDAC. However, the cellular basis for p53 action during PDAC development has not been explored in detail. Here, we leverage a hyperactive p53 variant—p53 53,54 —which we previously showed is a more robust PDAC suppressor than wild-type p53, to elucidate how p53 acts at the cellular level to dampen PDAC development. Using both inflammation-induced and KRAS G12D -driven PDAC models, we find that p53 53,54 both limits ADM accumulation and suppresses PanIN cell proliferation and does so more effectively than wild-type p53. Moreover, p53 53,54 suppresses KRAS signaling in PanINs and limits effects on the extracellular matrix (ECM) remodeling. While p53 53,54 has highlighted these functions, we find that pancreata in wild-type p53 mice similarly show less ADM, as well as reduced PanIN cell proliferation, KRAS signaling, and ECM remodeling relative to Trp53 -null mice. We find further that p53 enhances chromatin accessibility at sites controlled by acinar cell identity transcription factors. These findings reveal that p53 acts at multiple stages to suppress PDAC, both by limiting metaplastic transformation of acini and by dampening KRAS signaling in PanINs, thus providing key new understanding of p53 function in PDAC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2211937120

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. p5353,54 restrains ADM in caerulein-treated mice. (A) Schematic representation of wild-type and TAD mutant p53 proteins (TAD—transcriptional activation domain, DBD–DNA binding domain, TET—tetramerization domain) and a summary of their respective transactivation and PDAC suppression activities. p5353,54 is able to hyperactivate a subset of p53 target genes. (B) Schematic of caerulein-induced acute pancreatitis and its sequelae within 1 wk after treatment, including ADM and formation of PanINs. (C) Representative histological images of lesions found in caerulein-treated 2-mo-old KC;Trp53+/+ and KC;Trp5353,54/53,54 mice 1 wk after caerulein-induced acute pancreatitis. Two H&E fields and a higher magnification field immunostained for AMYLASE (AMY), CYTOKERATIN 19 (CK19) and DAPI are shown for each genotype. (D) Quantification of pancreatic transdifferentiation in entire pancreas using two different parameters: (Left) The percentage of acinar area relative to the whole pancreas ± SD based on H&E staining and (Right) the number of pancreatic lobes with ADM ± SD based on H&E staining (n = 4 for KC;Trp53+/+ cohort and n = 6 for KC;Trp5353,54/53,54 cohort. (E) Representative p53 immunostaining in ADM in KC;Trp53+/+ and KC;Trp5353,54/53,54 mice. (F) Ex vivo ADM assay in TGFα-treated acini from Trp53+/+ and Trp5353,54/53,54 mice. (Top) Representative brightfield images of acinar cultures showing the presence of ductal-like spheroid structures (arrowheads) in the midst of acinar cells (asterisks). (Middle) High magnification view of ductal and acinar structures using brightfield microscopy and (Bottom) High-magnification view of ductal and acinar structures immunostained for AMY, CK19 and DAPI (G) Average percentage of ADM ± SEM in independent biological replicates (n = 4 for both Trp53+/+ and Trp5353,54/53,54 cohorts), measured based on the morphological appearance of seeded acini. Normal acini show a grape-like clustered shape, while metaplastic acini undergoing ADM acquire a bubble-like shape. ** and *** represent P ≤ 0.01 and 0.001, respectively, based on the two-tailed unpaired Student’s t test. Blue and pink circles represent individual KC;Trp53+/+ and KC;Trp5353,54/53,54 mice respectively.
Fig. 1. p5353,54 restrains ADM in caerulein-treated mice. (A) Schematic representation of wild-type and TAD mutant p53 proteins (TAD—transcriptional activation domain, DBD–DNA binding domain, TET—tetramerization domain) and a summary of their respective transactivation and PDAC suppression activities. p5353,54 is able to hyperactivate a subset of p53 target genes. (B) Schematic of caerulein-induced acute pancreatitis and its sequelae within 1 wk after treatment, including ADM and formation of PanINs. (C) Representative histological images of lesions found in caerulein-treated 2-mo-old KC;Trp53+/+ and KC;Trp5353,54/53,54 mice 1 wk after caerulein-induced acute pancreatitis. Two H&E fields and a higher magnification field immunostained for AMYLASE (AMY), CYTOKERATIN 19 (CK19) and DAPI are shown for each genotype. (D) Quantification of pancreatic transdifferentiation in entire pancreas using two different parameters: (Left) The percentage of acinar area relative to the whole pancreas ± SD based on H&E staining and (Right) the number of pancreatic lobes with ADM ± SD based on H&E staining (n = 4 for KC;Trp53+/+ cohort and n = 6 for KC;Trp5353,54/53,54 cohort. (E) Representative p53 immunostaining in ADM in KC;Trp53+/+ and KC;Trp5353,54/53,54 mice. (F) Ex vivo ADM assay in TGFα-treated acini from Trp53+/+ and Trp5353,54/53,54 mice. (Top) Representative brightfield images of acinar cultures showing the presence of ductal-like spheroid structures (arrowheads) in the midst of acinar cells (asterisks). (Middle) High magnification view of ductal and acinar structures using brightfield microscopy and (Bottom) High-magnification view of ductal and acinar structures immunostained for AMY, CK19 and DAPI (G) Average percentage of ADM ± SEM in independent biological replicates (n = 4 for both Trp53+/+ and Trp5353,54/53,54 cohorts), measured based on the morphological appearance of seeded acini. Normal acini show a grape-like clustered shape, while metaplastic acini undergoing ADM acquire a bubble-like shape. ** and *** represent P ≤ 0.01 and 0.001, respectively, based on the two-tailed unpaired Student’s t test. Blue and pink circles represent individual KC;Trp53+/+ and KC;Trp5353,54/53,54 mice respectively.CC BY-NC-ND · PubMed Central
Fig. 2. p5353,54 Restrains PanIN Progression in Caerulein-Treated Mice. (A) Representative histological images of PanINs found in caerulein-treated KC;Trp53+/+ and KC;Trp5353,54/53,54 mice 1 wk after caerulein treatment. H&E, Alcian Blue, MUC5AC, and KI67 staining are shown. (B) The number of MUC5AC positive cells per square millimeter in pancreata (n = 4 for KC;Trp53+/+ cohort and n = 6 for KC;Trp5353,54/53,54 cohort, a total of 25 fields per mouse were counted). (C) The percentage of Alcian Blue-positive PanIN cells that were KI67 positive in pancreata of each cohort (n = 4 for KC;Trp53+/+ cohort and n = 6 for KC;Trp5353,54/53,54 cohort, a total of 25 fields per mouse were counted). (D) Representative SA-βgalactosidase staining in pancreata. (E) Representative p53 immunostaining in PanINs, as identified by Alcian Blue staining (F) Representative H&E images showing PanINs and surrounding ECM remodeling. (G) The percentage of PanINs in entire pancreas, based on MUC5AC staining, that show low ECM remodeling, defined by H&E analysis, ± SD from (n = 4 and 6 for KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively). (H) Masson’s Trichrome staining in pancreata of mice from both cohorts. (I) Representative images of PanINs, marked by Alcian Blue staining, showing phospho-ERK1/2 staining. (J) The percentage of PanINs in entire pancreas with negative/weak, moderate or high levels of phospho-ERK1/2 ± SD (n = 4 and six mice for KC; Trp53+/+ and KC; Trp5353,54/53,54 mice, respectively), based on phospho-ERK1/2/Alcian Blue immunostaining. Data represent mean ± SD; *, ** and *** represent P ≤ 0.05, 0.01 and 0.001, respectively, based on the two-tailed unpaired Student’s t test. Blue and pink circles represent individual KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively.
Fig. 2. p5353,54 Restrains PanIN Progression in Caerulein-Treated Mice. (A) Representative histological images of PanINs found in caerulein-treated KC;Trp53+/+ and KC;Trp5353,54/53,54 mice 1 wk after caerulein treatment. H&E, Alcian Blue, MUC5AC, and KI67 staining are shown. (B) The number of MUC5AC positive cells per square millimeter in pancreata (n = 4 for KC;Trp53+/+ cohort and n = 6 for KC;Trp5353,54/53,54 cohort, a total of 25 fields per mouse were counted). (C) The percentage of Alcian Blue-positive PanIN cells that were KI67 positive in pancreata of each cohort (n = 4 for KC;Trp53+/+ cohort and n = 6 for KC;Trp5353,54/53,54 cohort, a total of 25 fields per mouse were counted). (D) Representative SA-βgalactosidase staining in pancreata. (E) Representative p53 immunostaining in PanINs, as identified by Alcian Blue staining (F) Representative H&E images showing PanINs and surrounding ECM remodeling. (G) The percentage of PanINs in entire pancreas, based on MUC5AC staining, that show low ECM remodeling, defined by H&E analysis, ± SD from (n = 4 and 6 for KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively). (H) Masson’s Trichrome staining in pancreata of mice from both cohorts. (I) Representative images of PanINs, marked by Alcian Blue staining, showing phospho-ERK1/2 staining. (J) The percentage of PanINs in entire pancreas with negative/weak, moderate or high levels of phospho-ERK1/2 ± SD (n = 4 and six mice for KC; Trp53+/+ and KC; Trp5353,54/53,54 mice, respectively), based on phospho-ERK1/2/Alcian Blue immunostaining. Data represent mean ± SD; *, ** and *** represent P ≤ 0.05, 0.01 and 0.001, respectively, based on the two-tailed unpaired Student’s t test. Blue and pink circles represent individual KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively.CC BY-NC-ND · PubMed Central
Fig. 3. p5353,54 Restrains Disease Progression in Aging Kras Mice. (A) Representative H&E images of 5-mo-old KC;Trp53+/+ and KC;Trp5353,54/53,54 mice. (B) The percentage of pancreas area comprising normal acini ± SD, based on H&E staining from n = 4 and 6 for KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively. Quantification was performed on the entire pancreas. (C) (Left) Representative Alcian Blue images and (Right) percentage of pancreas area comprising PanINs, based on Alcian Blue staining, ± SD for each cohort (n = 4 and 6 for KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively). Quantification was performed on the entire pancreas. (D) (Left) Representative Alcian Blue (to mark PanIN lesions) and KI67 immunostaining for each cohort is shown. (Right) Quantification of KI67-positive Alcian Blue-positive PanIN cells ± SD (n = 4 and 6 for KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively). A total of 25 fields per mouse were counted. (E) Representative Masson’s Trichrome staining in pancreata of mice from each cohort. (F) Representative images of phospho-ERK1/2/Alcian Blue immunostaining for each cohort. (G) The percentage of PanINs with negative/weak, moderate or high levels of phospho-ERK1/2 ± SD from n = 4 and 6 for KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively. Quantification was performed on the entire pancreas. Data represents mean ± SD; *, ** and *** represent P ≤ 0.05, 0.01 and 0.001, respectively, based on the two-tailed unpaired Student’s t test. Blue and pink circles represent individual KC;Trp53+/+ and KC;Trp5353,54/53,54 mice respectively.
Fig. 3. p5353,54 Restrains Disease Progression in Aging Kras Mice. (A) Representative H&E images of 5-mo-old KC;Trp53+/+ and KC;Trp5353,54/53,54 mice. (B) The percentage of pancreas area comprising normal acini ± SD, based on H&E staining from n = 4 and 6 for KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively. Quantification was performed on the entire pancreas. (C) (Left) Representative Alcian Blue images and (Right) percentage of pancreas area comprising PanINs, based on Alcian Blue staining, ± SD for each cohort (n = 4 and 6 for KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively). Quantification was performed on the entire pancreas. (D) (Left) Representative Alcian Blue (to mark PanIN lesions) and KI67 immunostaining for each cohort is shown. (Right) Quantification of KI67-positive Alcian Blue-positive PanIN cells ± SD (n = 4 and 6 for KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively). A total of 25 fields per mouse were counted. (E) Representative Masson’s Trichrome staining in pancreata of mice from each cohort. (F) Representative images of phospho-ERK1/2/Alcian Blue immunostaining for each cohort. (G) The percentage of PanINs with negative/weak, moderate or high levels of phospho-ERK1/2 ± SD from n = 4 and 6 for KC;Trp53+/+ and KC;Trp5353,54/53,54 mice, respectively. Quantification was performed on the entire pancreas. Data represents mean ± SD; *, ** and *** represent P ≤ 0.05, 0.01 and 0.001, respectively, based on the two-tailed unpaired Student’s t test. Blue and pink circles represent individual KC;Trp53+/+ and KC;Trp5353,54/53,54 mice respectively.CC BY-NC-ND · PubMed Central
Fig. 4. Wild-Type p53 Restrains ADM and PanINs in Aging KrasG12D Mice. (A) Representative histological images of lesions found in 7-wk-old KC;Trp53+/+ and KC;Trp53fl/fl mice. H&E staining and immunostaining for AMYLASE (AMY), CYTOKERATIN 19 (CK19) and DAPI are shown for each genotype. (B) The percentage of pancreas area comprising normal acinar cells ± SD (n = 3 for both KC;Trp53+/+ and KC;Trp53fl/fl mice). Quantification was performed on the entire pancreas, based on H&E staining. (C) Two representative H&E and p53 immunohistochemistry images of 7-wk-old KC;Trp53+/+mice showing p53 positive cells in ADM areas. (D) Representative H&E images of PanINs found in 7-wk-old KC;Trp53+/+ and KC;Trp53fl/fl mice. (E) (Left) Representative Alcian Blue (a marker of PanINs) and CK19 (a marker of normal ducts, PanINs and PDAC) staining, (Right) quantification of Alcian Blue and CK19 positive area ± SD from KC;Trp53+/+ and KC;Trp53fl/fl mouse pancreata (n = 3 for both KC;Trp53+/+ and KC;Trp53fl/fl mice). Quantification was performed on the entire pancreas. (F) (Left) Representative Alcian Blue and KI67 staining for each genotype and (Right) quantification of Alcian Blue-positive PanIN cells that are KI67 positive (arrows) ± SD (n = 3 for both KC;Trp53+/+ and KC;Trp53fl/fl mice). Quantification was performed by counting positive cells in a total of 25 fields per mouse, as described in Materials and Methods. (G) Representative Masson’s Trichrome stain in pancreata of each genotype. (H) Schematic of the different steps at which p53 can impede PDAC development. p53 can inhibit ADM and consequent PanIN formation, as well as PanIN cell proliferation. Data represent mean ± SD; * represents P ≤ 0.05, based on the two-tailed unpaired Student’s t test. Blue and red circles represent individual KC;Trp53+/+ and KC;Trp53fl/fl mice, respectively.
Fig. 4. Wild-Type p53 Restrains ADM and PanINs in Aging KrasG12D Mice. (A) Representative histological images of lesions found in 7-wk-old KC;Trp53+/+ and KC;Trp53fl/fl mice. H&E staining and immunostaining for AMYLASE (AMY), CYTOKERATIN 19 (CK19) and DAPI are shown for each genotype. (B) The percentage of pancreas area comprising normal acinar cells ± SD (n = 3 for both KC;Trp53+/+ and KC;Trp53fl/fl mice). Quantification was performed on the entire pancreas, based on H&E staining. (C) Two representative H&E and p53 immunohistochemistry images of 7-wk-old KC;Trp53+/+mice showing p53 positive cells in ADM areas. (D) Representative H&E images of PanINs found in 7-wk-old KC;Trp53+/+ and KC;Trp53fl/fl mice. (E) (Left) Representative Alcian Blue (a marker of PanINs) and CK19 (a marker of normal ducts, PanINs and PDAC) staining, (Right) quantification of Alcian Blue and CK19 positive area ± SD from KC;Trp53+/+ and KC;Trp53fl/fl mouse pancreata (n = 3 for both KC;Trp53+/+ and KC;Trp53fl/fl mice). Quantification was performed on the entire pancreas. (F) (Left) Representative Alcian Blue and KI67 staining for each genotype and (Right) quantification of Alcian Blue-positive PanIN cells that are KI67 positive (arrows) ± SD (n = 3 for both KC;Trp53+/+ and KC;Trp53fl/fl mice). Quantification was performed by counting positive cells in a total of 25 fields per mouse, as described in Materials and Methods. (G) Representative Masson’s Trichrome stain in pancreata of each genotype. (H) Schematic of the different steps at which p53 can impede PDAC development. p53 can inhibit ADM and consequent PanIN formation, as well as PanIN cell proliferation. Data represent mean ± SD; * represents P ≤ 0.05, based on the two-tailed unpaired Student’s t test. Blue and red circles represent individual KC;Trp53+/+ and KC;Trp53fl/fl mice, respectively.CC BY-NC-ND · PubMed Central
Fig. 5. p53 Promotes Chromatin Accessibility at Sites Controlled by Acinar Cell Identity Transcription Factors. (A) Representative H&E images of the pancreas of 3-mo-old and 1-mo-old KC;Trp53+/+ and KC;Trp53fl/fl mice used for ATAC-seq experiments. (B) Schematic representation of the experimental steps for ATAC-seq experiments. (C) Scatter plot of log-twofold change differences between p53-proficient and p53-deficient acini, versus the Log2 mean accessibility. Red (enhanced accessibility) and blue (decreased accessibility) indicate significant accessibility changes. (D) (Left) LOLA analysis of regions that are more accessible in the presence of p53 using pancreas ChIP-seq data sets and (Right) Homer motif analysis of the factors found enriched by LOLA (E) Accessibility tracks from p53-proficient and deficient acini, for acinar genes controlled by RBPJL and PTF1A, as well as RBPJL and PTF1A ChIP-seq tracks. (F) Schematic of the role of p53 in promoting chromatin accessibility at pro-acinar identity genes.
Fig. 5. p53 Promotes Chromatin Accessibility at Sites Controlled by Acinar Cell Identity Transcription Factors. (A) Representative H&E images of the pancreas of 3-mo-old and 1-mo-old KC;Trp53+/+ and KC;Trp53fl/fl mice used for ATAC-seq experiments. (B) Schematic representation of the experimental steps for ATAC-seq experiments. (C) Scatter plot of log-twofold change differences between p53-proficient and p53-deficient acini, versus the Log2 mean accessibility. Red (enhanced accessibility) and blue (decreased accessibility) indicate significant accessibility changes. (D) (Left) LOLA analysis of regions that are more accessible in the presence of p53 using pancreas ChIP-seq data sets and (Right) Homer motif analysis of the factors found enriched by LOLA (E) Accessibility tracks from p53-proficient and deficient acini, for acinar genes controlled by RBPJL and PTF1A, as well as RBPJL and PTF1A ChIP-seq tracks. (F) Schematic of the role of p53 in promoting chromatin accessibility at pro-acinar identity genes.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 1

  1. S. S. Mello F. Müller S. K. Denny W. J. Greenleaf L. D. Attardi The role of p53 in pancreatic cancer suppression. GEO. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE224744. Deposited 7 February 2023.

Cited by

See all 61

Metadata

Authors
Mello, S. S., Flowers, B. M., Mazur, P. K., Lee, J. J., Müller, F., Denny, S. K., Ferreira, S., Hanson, K., Kim, S. K., Greenleaf, W. J., Wood, L. D., & Attardi, L. D.
Affiliations
  • University of Rochester Medicine (US)
  • Stanford Medicine (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Johns Hopkins University (US)
Corresponding author
Attardi, Laura D.
Venue
Proceedings of the National Academy of Sciences
Published
2023-02-27
Volume
120
Issue
10
Pages
e2211937120-e2211937120
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4322421452
Cited by
55
References
61
Citations by year
2026: 18 · 2025: 17 · 2024: 16 · 2023: 4
FWCI
6.71
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
HHS | NIH | National Cancer Institute (R21 CA169673, R01 CA140875, R35 CA197591)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
p53, pancreatic ductal adenocarcinoma, TP53 mutation, acinar-to-ductal metaplasia, pancreatic intraepithelial neoplasia, KRAS G12D, KRAS signaling, extracellular matrix remodeling, chromatin accessibility, premalignant pancreatic lesions, tumor suppression
MeSH terms
Animals, Anophthalmos, Humans, Lung Diseases, Metaplasia, Microphthalmos, Pancreas, Pancreatic Neoplasms, Precancerous Conditions, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Mice, Knockout, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multifaceted role for p53 in pancreatic cancer suppression. https://app.cochat.ai/papers/10.1073/pnas.2211937120
The paper
Mello, S. S., Flowers, B. M., Mazur, P. K., Lee, J. J., Müller, F., Denny, S. K., Ferreira, S., Hanson, K., Kim, S. K., Greenleaf, W. J., Wood, L. D., & Attardi, L. D. (2023). Multifaceted role for p53 in pancreatic cancer suppression. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2211937120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.